



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

Date: April 8, 2022

To,

|   |  |
|---|--|
| The Corporate Services Department,<br>Bombay Stock Exchange Limited<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai- 400 001<br>Scrip Code: 543434 | Manager - Listing Department<br>The National Stock Exchange of India Ltd.<br>Exchange Plaza, Plot no. C/1, G Block,<br>Bandra-Kurla Complex<br>Bandra (E), Mumbai - 400 051<br>NSE Symbol: SUPRIYA |
|---|--|

Dear Sir/Madam,

**Subject: Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2022**

Please find enclosed herewith a duly signed Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended March 31, 2022.

You are requested to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh  
Company Secretary & Compliance Officer  
Membership No.: A44973



Encl: a/a

**Corporate Office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

**CIN: L51900MH2008PLC180452** |E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) |Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**

Date: 07.04.2022

To,  
Company Secretary  
Supriya Lifescience Limited

**Subject: Confirmation Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.**

Dear Sir,

In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 31<sup>st</sup> March, 2022, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed.

SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2022/26 dated February 25, 2022 as an extension to SEBI Circular on "Relaxation in adherence to prescribed timelines issued by SEBI due to Covid-19" dated April 13, 2020 and April 29, 2021, whereby relaxation was given to intermediaries / market participants w.r.t. compliance with the prescribed timelines up to June 30, 2022 and granted an additional 30 days over the prescribed timelines for completion of service requests mentioned in the circular dated February 25, 2022 which included processing of demat and remat requests. We hereby also confirm that the security certificates received for dematerialisation have been confirmed/rejected and the security certificates received were mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in the register of members as the registered owner within the prescribed timelines.. We request you to kindly take note of the above in your records.

**Note: We have not received any demat/remat request during the period 01.01.2022 to 31.03.2022 for Supriya Lifescience Limited. The certificate is issued for compliance purpose only.**

Thanking You,

Yours faithfully,  
For Link Intime India Pvt. Ltd



Balaji Sharma  
Vice President-Corporate Registry